Gefitinib. Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 515-516

  Muhsin, Mohamed ^a   Graham, Joanne ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Intl   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GSK 572016; PLATINUM; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; QUINAZOLINE DERIVATIVE;

CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; NOTE; PRIORITY JOURNAL; PROGNOSIS; UNITED STATES; ARTICLE; LUNG TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 0038678969     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1136     Document Type: Note

References (9)

1. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-S66 (2001).
2. Cersosimo, R. J. Lung cancer: a review. Am. J. Health Syst. Pharm. 59, 611-642 (2002).
3. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for the treatment of cancer. Nature Rev. Drug Discov. 2, 325-334 (2003).
4. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
5. Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7(S4), 2-8 (2002).
6. Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
7. Barker, A. J. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914 (2001).
8. FDA Drug Approvals List [online] (cited 28 May 2003) http://www.fda.gov/cder/foi/label/2003/21399_iressa_lbl.pdf (2003).
9. Wakeling, A. E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749-5754 (2002).